ABEO Abeona Therapeutics Inc.

7.37
-0.21  -3%
Previous Close 7.58
Open 7.6
Price To Book 2.35
Market Cap 353111139
Shares 47,944,486
Volume 514,097
Short Ratio
Av. Daily Volume 708,825

SEC filingsSee all SEC filings

  1. 8-K - Current report 181220121
  2. 8-K - Current report 181209612
  3. 8-K - Current report 181173732
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173135
  5. 8-K - Current report 181161607

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 ongoing as of December 6, 2018.
ABO-101
Sanfilippo syndrome type B (MPS IIIB)
Pivotal trial to be initiated mid-2019.
EB-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 updated data released February 8, 2018. CSF heparan sulfate levels decreased 57%/64%.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Is Abeona Therapeutics Inc (ABEO) A Good Stock To Buy?
  2. Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
  3. Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump
  4. Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
  5. Moving Average Crossover Alert: Abeona Therapeutics
  6. Abeona Therapeutics to Host R&D Day on December 6, 2018
  7. Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  8. Abeona Therapeutics Announces CEO Transition
  9. Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
  10. Edited Transcript of ABEO earnings conference call or presentation 12-Nov-18 3:00pm GMT
  11. Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates
  12. Abeona Therapeutics: 3Q Earnings Snapshot
  13. Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
  14. What Kind Of Share Price Volatility Should You Expect For Abeona Therapeutics Inc (NASDAQ:ABEO)?
  15. Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
  16. REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
  17. Abeona Therapeutics Appoints João Siffert, M.D. Head of Research and Development and Chief Medical Officer
  18. Investor Expectations to Drive Momentum within Cincinnati Bell, Hooker Furniture, AgroFresh Solutions, Forward Industries, Abeona Therapeutics, and Sientra — Discovering Underlying Factors of Influence
  19. How Abeona Therapeutics Stock Is Doing
  20. Abeona Announces Participation at Upcoming Conferences

SEC Filings

  1. 8-K - Current report 181220121
  2. 8-K - Current report 181209612
  3. 8-K - Current report 181173732
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173135
  5. 8-K - Current report 181161607
  6. 8-K/A [Amend] - Current report 181114075
  7. 8-K - Current report 181108587
  8. 8-K - Current report 181026900
  9. 424B5 - Prospectus [Rule 424(b)(5)] 181026548
  10. 8-K - Current report 181024080